{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:53:14Z","timestamp":1790963594030,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,18]],"date-time":"2021-02-18T00:00:00Z","timestamp":1613606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Ibrutinib inhibits Bruton tyrosine kinase while venetoclax is a specific inhibitor of the anti-apoptotic protein BCL2. Both drugs are highly effective as monotherapy against chronic lymphocytic leukemia (CLL), and clinical trials using the combination therapy have produced remarkable results in terms of rate of complete remission and frequency of undetectable minimal residual disease. However, the laboratory rationale behind the success of the drug combination is still lacking. A better understanding of how these two drugs synergize would eventually help develop other rational combination strategies. Using an ex vivo model that promotes CLL proliferation, we show that modeled ibrutinib proliferative responses, but not viability responses, correlate well with patients\u2019 actual clinical responses. Importantly, we demonstrate for the first time that ibrutinib and venetoclax act on distinct CLL subpopulations that have different proliferative capacities. While the dividing subpopulation of CLL responds to ibrutinib, the resting subpopulation preferentially responds to venetoclax. The combination of these targeted therapies effectively reduced both the resting and dividing subpopulations in most cases. Our laboratory findings help explain several clinical observations and contribute to the understanding of tumor dynamics. Additionally, our proliferation model may be used to identify novel drug combinations with the potential of eradicating residual disease.<\/jats:p>","DOI":"10.1038\/s41408-021-00429-z","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T07:10:53Z","timestamp":1613805053000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Ibrutinib and venetoclax target distinct subpopulations of CLL cells: implication for residual disease eradication"],"prefix":"10.1038","volume":"11","author":[{"given":"Pin","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2296-1577","authenticated-orcid":false,"given":"Shengchun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie A.","family":"Franzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Girish","family":"Venkataraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"McClure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nifang","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1843-7038","authenticated-orcid":false,"given":"Madina","family":"Sukhanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald A.","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Nejati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariusz A.","family":"Wasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juehua","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9168-3203","authenticated-orcid":false,"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0773-1212","authenticated-orcid":false,"given":"Y. Lynn","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,18]]},"reference":[{"key":"429_CR1","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1056\/NEJM199510193331606","volume":"333","author":"C Rozman","year":"1995","unstructured":"Rozman, C. & Montserrat, E. Chronic lymphocytic leukemia. N. Engl. J. Med. 333, 1052\u20131057 (1995).","journal-title":"N. Engl. J. Med."},{"key":"429_CR2","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1056\/NEJMra041720","volume":"352","author":"N Chiorazzi","year":"2005","unstructured":"Chiorazzi, N., Rai, K. R. & Ferrarini, M. Chronic lymphocytic leukemia. N. Engl. J. Med. 352, 804\u2013815 (2005).","journal-title":"N. Engl. J. Med."},{"key":"429_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 369, 32\u201342 (2013).","journal-title":"N. Engl. J. Med."},{"key":"429_CR4","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"429_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1182\/blood.2018882555","volume":"134","author":"AW Roberts","year":"2019","unstructured":"Roberts, A. W. et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood 134, 111\u2013122 (2019).","journal-title":"Blood"},{"key":"429_CR6","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.jmoldx.2020.06.004","volume":"22","author":"J Lee","year":"2020","unstructured":"Lee, J. & Wang, Y. L. Prognostic and predictive molecular biomarkers in chronic lymphocytic leukemia. J. Mol. Diagn. 22, 1114\u20131125 (2020).","journal-title":"J. Mol. Diagn."},{"key":"429_CR7","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.19.00894","volume":"37","author":"P Hillmen","year":"2019","unstructured":"Hillmen, P. et al. Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY Study. J. Clin. Oncol. 37, 2722\u20132729 (2019).","journal-title":"J. Clin. Oncol."},{"key":"429_CR8","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain, N. et al. Ibrutinib and venetoclax for first-line treatment of CLL. N. Engl. J. Med. 380, 2095\u20132103 (2019).","journal-title":"N. Engl. J. Med."},{"key":"429_CR9","doi-asserted-by":"publisher","first-page":"752","DOI":"10.3324\/haematol.2009.006676","volume":"94","author":"S Deaglio","year":"2009","unstructured":"Deaglio, S. & Malavasi, F. Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. Haematologica 94, 752\u2013756 (2009).","journal-title":"Haematologica"},{"key":"429_CR10","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1172\/JCI23409","volume":"115","author":"BT Messmer","year":"2005","unstructured":"Messmer, B. T. et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Investig. 115, 755\u2013764 (2005).","journal-title":"J. Clin. Investig."},{"key":"429_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.1365-2559.1994.tb00553.x","volume":"24","author":"C Schmid","year":"1994","unstructured":"Schmid, C. & Isaacson, P. G. Proliferation centres in B-cell malignant lymphoma, lymphocytic (B-CLL): an immunophenotypic study. Histopathology 24, 445\u2013451 (1994).","journal-title":"Histopathology"},{"key":"429_CR12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S0046-8177(99)90089-8","volume":"30","author":"IA Lampert","year":"1999","unstructured":"Lampert, I. A., Wotherspoon, A., Van, Noorden, S. & Hasserjian, R. P. High expression of CD23 in the proliferation centers of chronic lymphocytic leukemia in lymph nodes and spleen. Hum. Pathol. 30, 648\u2013654 (1999).","journal-title":"Hum. Pathol."},{"key":"429_CR13","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/nrc.2016.8","volume":"16","author":"G Fabbri","year":"2016","unstructured":"Fabbri, G. & Dalla-Favera, R. The molecular pathogenesis of chronic lymphocytic leukaemia. Nat. Rev. Cancer 16, 145\u2013162 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"429_CR14","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3324\/haematol.2010.022277","volume":"95","author":"E Gine","year":"2010","unstructured":"Gine, E. et al. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia (\u201caccelerated\u201d chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica 95, 1526\u20131533 (2010).","journal-title":"Haematologica"},{"key":"429_CR15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1158\/1078-0432.CCR-09-1519","volume":"16","author":"Z Song","year":"2010","unstructured":"Song, Z. et al. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. Clin. Cancer Res. 16, 587\u2013599 (2010).","journal-title":"Clin. Cancer Res."},{"key":"429_CR16","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.1182\/blood-2011-01-328484","volume":"117","author":"SE Herman","year":"2011","unstructured":"Herman, S. E. et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117, 6287\u20136296 (2011).","journal-title":"Blood"},{"key":"429_CR17","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.hoc.2013.01.002","volume":"27","author":"Y Herishanu","year":"2013","unstructured":"Herishanu, Y., Katz, B. Z., Lipsky, A. & Wiestner, A. Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. Hematol. Oncol. Clin. N. Am. 27, 173\u2013206 (2013).","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"429_CR18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.semcancer.2013.06.010","volume":"24","author":"F Caligaris-Cappio","year":"2014","unstructured":"Caligaris-Cappio, F., Bertilaccio, M. T. & Scielzo, C. How the microenvironment wires the natural history of chronic lymphocytic leukemia. Semin. Cancer Biol. 24, 43\u201348 (2014).","journal-title":"Semin. Cancer Biol."},{"key":"429_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.45","volume":"3","author":"P Oppezzo","year":"2013","unstructured":"Oppezzo, P. & Dighiero, G. Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia. Blood Cancer J. 3, e149 (2013).","journal-title":"Blood Cancer J."},{"key":"429_CR20","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1182\/blood-2009-07-233718","volume":"114","author":"AV Kurtova","year":"2009","unstructured":"Kurtova, A. V. et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 114, 4441\u20134450 (2009).","journal-title":"Blood"},{"key":"429_CR21","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1089\/scd.2014.0229","volume":"23","author":"A Janel","year":"2014","unstructured":"Janel, A. et al. The chronic lymphocytic leukemia clone disrupts the bone marrow microenvironment. Stem Cells Dev. 23, 2972\u20132982 (2014).","journal-title":"Stem Cells Dev."},{"key":"429_CR22","doi-asserted-by":"publisher","first-page":"7632","DOI":"10.18632\/oncotarget.2939","volume":"6","author":"N Purroy","year":"2015","unstructured":"Purroy, N. et al. Co-culture of primary CLL cells with bone marrow mesenchymal cells, CD40 ligand and CpG ODN promotes proliferation of chemoresistant CLL cells phenotypically comparable to those proliferating in vivo. Oncotarget 6, 7632\u20137643 (2015).","journal-title":"Oncotarget"},{"key":"429_CR23","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","volume":"30","author":"S Bottcher","year":"2012","unstructured":"Bottcher, S. et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J. Clin. Oncol. 30, 980\u2013988 (2012).","journal-title":"J. Clin. Oncol."},{"key":"429_CR24","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/jez.b.22646","volume":"324","author":"C Bai","year":"2015","unstructured":"Bai, C. et al. Multi-lineage potential research of bone marrow mesenchymal stem cells from Bama miniature pig. J. Exp. Zool. Part B 324, 671\u2013685 (2015).","journal-title":"J. Exp. Zool. Part B"},{"key":"429_CR25","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/leu.2014.263","volume":"29","author":"S Cheng","year":"2015","unstructured":"Cheng, S. et al. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia 29, 895\u2013900 (2015).","journal-title":"Leukemia"},{"key":"429_CR26","doi-asserted-by":"publisher","first-page":"4598","DOI":"10.18632\/oncotarget.6727","volume":"7","author":"A Guo","year":"2016","unstructured":"Guo, A. et al. Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. Oncotarget 7, 4598\u20134610 (2016).","journal-title":"Oncotarget"},{"key":"429_CR27","doi-asserted-by":"publisher","first-page":"12953","DOI":"10.18632\/oncotarget.14588","volume":"8","author":"A Guo","year":"2017","unstructured":"Guo, A. et al. Dual SYK\/JAK inhibition overcomes ibrutinib resistance in chronic lymphocytic leukemia: Cerdulatinib, but not ibrutinib, induces apoptosis of tumor cells protected by the microenvironment. Oncotarget 8, 12953\u201312967 (2017).","journal-title":"Oncotarget"},{"key":"429_CR28","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1038\/onc.2016.494","volume":"36","author":"A Guo","year":"2017","unstructured":"Guo, A. et al. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment. Oncogene 36, 3441\u20133449 (2017).","journal-title":"Oncogene"},{"key":"429_CR29","doi-asserted-by":"publisher","first-page":"901","DOI":"10.4049\/jimmunol.1403189","volume":"195","author":"PK Mongini","year":"2015","unstructured":"Mongini, P. K. et al. TLR-9 and IL-15 synergy promotes the in vitro clonal expansion of chronic lymphocytic leukemia B cells. J. Immunol. 195, 901\u2013923 (2015).","journal-title":"J. Immunol."},{"key":"429_CR30","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.4049\/jimmunol.1800591","volume":"201","author":"R Gupta","year":"2018","unstructured":"Gupta, R. et al. Mechanistic insights into CpG DNA and IL-15 synergy in promoting B cell chronic lymphocytic leukemia clonal expansion. J. Immunol. 201, 1570\u20131585 (2018).","journal-title":"J. Immunol."},{"key":"429_CR31","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.2119\/molmed.2011.00360","volume":"17","author":"C Calissano","year":"2011","unstructured":"Calissano, C. et al. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born\/divided and older\/quiescent cells. Mol. Med. 17, 1374\u20131382 (2011).","journal-title":"Mol. Med."},{"key":"429_CR32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1038\/leu.2013.358","volume":"28","author":"S Cheng","year":"2014","unstructured":"Cheng, S. et al. BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity. Leukemia 28, 649\u2013657 (2014).","journal-title":"Leukemia"},{"key":"429_CR33","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1200\/JCO.2012.42.7906","volume":"31","author":"RH Advani","year":"2013","unstructured":"Advani, R. H. et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed\/refractory B-cell malignancies. J. Clin. Oncol. 31, 88\u201394 (2013).","journal-title":"J. Clin. Oncol."},{"key":"429_CR34","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/bjh.12974","volume":"166","author":"J Ma","year":"2014","unstructured":"Ma, J. et al. Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. Br. J. Haematol. 166, 849\u2013861 (2014).","journal-title":"Br. J. Haematol."},{"key":"429_CR35","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","volume":"17","author":"M Ming","year":"2018","unstructured":"Ming, M. et al. XPO1 inhibitor selinexor overcomes intrinsic ibrutinib resistance in mantle cell lymphoma via nuclear retention of IkappaB. Mol. Cancer Ther. 17, 2564\u20132574 (2018).","journal-title":"Mol. Cancer Ther."},{"key":"429_CR36","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1056\/NEJMc1402716","volume":"370","author":"RR Furman","year":"2014","unstructured":"Furman, R. R. et al. Ibrutinib resistance in chronic lymphocytic leukemia. N. Engl. J. Med. 370, 2352\u20132354 (2014).","journal-title":"N. Engl. J. Med."},{"key":"429_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.89904","volume":"2","author":"JA Burger","year":"2017","unstructured":"Burger, J. A. et al. Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight 2, e89904 (2017).","journal-title":"JCI Insight"},{"key":"429_CR38","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1124\/dmd.116.071613","volume":"45","author":"H Liu","year":"2017","unstructured":"Liu, H. et al. Metabolism and disposition of a novel B-cell lymphoma-2 inhibitor venetoclax in humans and characterization of its unusual metabolites. Drug Metabol. Dispos. 45, 294\u2013305 (2017).","journal-title":"Drug Metabol. Dispos."},{"key":"429_CR39","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1182\/blood-2011-11-390989","volume":"119","author":"MF de Rooij","year":"2012","unstructured":"de Rooij, M. F. et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119, 2590\u20132594 (2012).","journal-title":"Blood"},{"key":"429_CR40","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1158\/1078-0432.CCR-15-0781","volume":"21","author":"SE Herman","year":"2015","unstructured":"Herman, S. E. et al. Treatment with ibrutinib inhibits BTK- and VLA-4-dependent adhesion of chronic lymphocytic leukemia cells in vivo. Clin. Cancer Res. 21, 4642\u20134651 (2015).","journal-title":"Clin. Cancer Res."},{"key":"429_CR41","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.1158\/1078-0432.CCR-14-2809","volume":"21","author":"F Cervantes-Gomez","year":"2015","unstructured":"Cervantes-Gomez, F. et al. Pharmacological and protein profiling suggests venetoclax (ABT-199) as optimal partner with ibrutinib in chronic lymphocytic leukemia. Clin. Cancer Res. 21, 3705\u20133715 (2015).","journal-title":"Clin. Cancer Res."},{"key":"429_CR42","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1038\/leu.2017.32","volume":"31","author":"J Deng","year":"2017","unstructured":"Deng, J. et al. Bruton\u2019s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Leukemia 31, 2075\u20132084 (2017).","journal-title":"Leukemia"},{"key":"429_CR43","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2013-09-527853","volume":"123","author":"JA Woyach","year":"2014","unstructured":"Woyach, J. A. et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 123, 1810\u20131817 (2014).","journal-title":"Blood"},{"key":"429_CR44","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1182\/blood-2010-05-284984","volume":"117","author":"Y Herishanu","year":"2011","unstructured":"Herishanu, Y. et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 117, 563\u2013574 (2011).","journal-title":"Blood"},{"key":"429_CR45","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","volume":"131","author":"S O\u2019Brien","year":"2018","unstructured":"O\u2019Brien, S. et al. Single-agent ibrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience. Blood 131, 1910\u20131919 (2018).","journal-title":"Blood"},{"key":"429_CR46","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13045-017-0435-x","volume":"10","author":"MK Kashyap","year":"2017","unstructured":"Kashyap, M. K. et al. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. J. Hematol. Oncol. 10, 112 (2017).","journal-title":"J. Hematol. Oncol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00429-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00429-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00429-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T10:40:17Z","timestamp":1669891217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00429-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,18]]},"references-count":46,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["429"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00429-z","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,18]]},"assertion":[{"value":"9 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.T., Speaker\u2019s bureau for Novartis. S.M., Consultancy for AstraZeneca, Bioverativ, Genentech, Janssen, Kite and Pharmacyclics, Speaker\u2019s bureau for AstraZeneca, Janssen and Pharmacyclics, and research funding from Abbvie, AstraZeneca, Beigene, Pharmacyclics, Juno and Novartis. N.K., advisory board for Pharmacyclics, Jessen and Seattle Genetics, and research funding from Bristol Meyer Squibb. Y.L.W., employment and stock ownership at Incyte Research Institute. All other authors declare no relevant conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"39"}}